Alan Huang, Tango’s chief scientific officer, joined the company initially as senior vice president, head of biology, after serving as a consultant at Third Rock Ventures, where he played a leading role in the creation and launch of Tango. Alan brings over 15 years of experience in oncology translational research, target discovery and drug development, most recently from Novartis Institute for Biomedical Research as senior director and interim global head of oncology translational research. In this role, Alan was responsible for generating trial enabling pre-clinical concepts to aid patient selection, biomarker, and combination strategies and worked alongside the clinical teams to implement and execute. Under his leadership, the group advanced many key Novartis pipeline compounds through development and registration. Prior to this, Alan was responsible for a variety of drug discovery and target ID platforms in oncology research. Most notably, he pioneered the pooled based shRNA screening technology. Prior to joining Novartis, Alan worked at Millennium Pharmaceuticals as senior scientist focusing on the discovery of novel targets to treat metabolic diseases.
Alan obtained his Bachelor of Science in biochemistry from Fudan University and his doctorate in biochemistry & molecular biology from the University of South Alabama. He completed a postdoctoral fellowship at Schepen’s Eye Research Institute of Harvard Medical School, studying the role of BCL2 in CNS axonal regeneration. Alan is an author on over 30 peer-reviewed publications and an inventor of nearly 20 patents.